TrialJournal of clinical pharmacology2021

Phase 1 Renal Impairment Trial Results Supports Targeted Individualized Dosing of ELX-02 in Patients With Nephropathic Cystinosis.

Thomas Haverty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.